Salopek T G, Marghoob A A, Slade J M, Rao B, Rigel D S, Kopf A W, Bart R S
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, USA.
Dermatol Surg. 1995 Apr;21(4):301-5. doi: 10.1111/j.1524-4725.1995.tb00177.x.
The incidence of malignant melanoma (MM) in the United States (US) must be known to accurately evaluate the costs that MM imposes on the health care system and society in general. Furthermore, knowledge of the incidence is needed to determine the benefit of MM prevention programs.
To obtain an estimate of the incidence of MM in the US.
The data for this study were collected by means of a questionnaire that was sent to all members of the American Academy of Dermatology practicing in the US (N = 7412).
Based on the mean number of MMs seen annually per dermatologist in each state and the number of dermatologists per state, the number of new in situ and invasive MMs in the US in 1992 was calculated to be 80,000. This translates to an incidence of 32 MMs per 100,000 persons.
Our estimate of 80,000 new MMs diagnosed in 1992 in the US suggests that MM places much greater burdens on the US health care system and society than that based on current published estimates.
必须了解美国恶性黑色素瘤（MM）的发病率，以便准确评估MM给医疗保健系统乃至整个社会带来的成本。此外，需要知晓发病率来确定MM预防项目的效益。
估算美国MM的发病率。
本研究数据通过向在美国执业的美国皮肤病学会所有成员（N = 7412）发送调查问卷收集。
根据每个州每位皮肤科医生每年诊治的MM平均数量以及每个州皮肤科医生的数量，计算出1992年美国新的原位和浸润性MM病例数为80,000例。这相当于每10万人中有32例MM发病。
我们对1992年美国新诊断出80,000例MM的估算表明，MM给美国医疗保健系统和社会带来的负担比目前公布的估算结果要大得多。
